Loading
Hepatocellular Carcinoma Treatment and Prognosis · Journal article
Cell Proliferation · August 14, 2026
Raises a question worth testing. It does not answer one.
This narrative review surveys the current state of liver organoid technology across disease modelling, drug screening, and regenerative medicine applications. It reports proof-of-concept findings in preclinical systems—including vascularized organoids, gene editing, and viral life-cycle support—but identifies substantial barriers (hepatocyte immaturity, vascular construction, lack of standardization) that prevent clinical translation. No original clinical efficacy data or human outcomes are presented.
Journal article. Patient-derived organoids, iPSC-derived organoids, tumour organoid biobanks, and animal models of acute liver failure; no human subjects studied..
Vascularized liver organoids achieved endothelial coverage exceeding 85% via endothelial co-culture Prime editing enabled precise pathogenic mutation correction in patient-derived organoids with no genome-wide off-target effects detected iPSC-derived liver organoids recapitulate MASLD pathological progression and verify semaglutide lipid-lowering efficacy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review identifies liver organoid technology as a promising preclinical platform but explicitly notes that clinical translation remains blocked by unresolved technical challenges. Clinicians should regard current applications as investigational tools for drug screening and disease modelling, not as established therapies.
This is a narrative review summarizing preclinical and in vitro organoid technologies without reporting original empirical data, clinical outcomes, or comparative efficacy in humans.
Quoted from the source exactly as published.
This review identifies liver organoid technology as a promising preclinical platform but explicitly notes that clinical translation remains blocked by unresolved technical challenges. Clinicians should regard current applications as investigational tools for drug screening and disease modelling, not as established therapies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Liver organoids are three-dimensional miniature liver models that recapitulate the complex architecture and key functions of the human liver in vitro, offering powerful platforms for both fundamental research and translational applications. This review systematically summarises current fabrication strategies, disease-modelling utilities and regenerative potentials of liver organoids, alongside the major challenges and future directions. In recent years, the field has witnessed several breakthroughs. Through endothelial co-culture approaches, vascularised and metabolically zonated liver organoids have been successfully generated, achieving endothelial coverage exceeding 85%. Prime editing enables precise correction of pathogenic mutations in patient-derived organoids, with no off-target effects detected at the genome-wide level. In disease modelling, iPSC-derived liver organoids faithfully recapitulate the pathological progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and verify the lipid-lowering efficacy of semaglutide. Macrophage-integrated organoid models support the full life cycles of HEV, SARS-CoV-2 and dengue virus, providing new tools for antiviral drug screening. Large-scale patient-derived tumour organoid biobanks successfully preserve the heterogeneity and clinical drug-resistance signatures of liver cancers. In regenerative medicine, encapsulated hepatocyte organoids and the UTOpiA bioartificial liver system have effectively rescued acute liver failure in animal models, while gene-edited autologous organoids offer potential curative strategies for genetic disorders such as Wilson disease. Nevertheless, insufficient hepatocyte functional maturity, difficulties in constructing vascular networks, and the lack of standardised culture protocols remain major obstacles to clinical translation. By bridging fundamental liver biology and clinical practice, liver organoid technology lays a solid foundation for precision hepatology and regenerative therapies. Continued interdisciplinary efforts are still required to overcome current limitations and facilitate its clinical adoption.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.